Results 21 to 30 of about 25,219 (211)

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT: Pharmacometrics & Systems Pharmacology, 2023
Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy.
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy   +8 more
doaj   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy

Hitit Medical Journal, 2020
An 80-year-old female was admitted to the hospital, presenting a pulsatile and painless mass on the right temporal site occurred one month ago following a blunt head trauma.
Sertan Özyalçın, Adem İlkay Diken, Adnan Yalçınkaya, Ufuk Türkmen   +3 more
doaj  

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways

BMC Pharmacology and Toxicology, 2019
Background Apixaban effectively lowers the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. Systemic exposure to a given apixaban dose depends on multiple clearance pathways.
Andrea Huppertz, Caspar Grond-Ginsbach, Chris Dumschat, Kathrin I. Foerster, Jürgen Burhenne, Johanna Weiss, David Czock, Jan C. Purrucker, Timolaos Rizos, Walter E. Haefeli   +9 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration

Frontiers in Veterinary Science, 2018
Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa, Marjory B. Brooks, Thomas Divers, Sally Ness, Ingvild Birschmann, Mark G. Papich, Tracy Stokol   +6 more
doaj   +1 more source

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, EarlyView.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations

Pharmaceutics, 2023
Apixaban and rivaroxaban have first-line use for many patients needing anticoagulation for venous thromboembolism (VTE). The pharmacokinetics of these drugs in non-obese subjects have been extensively studied, and, while changes in pharmacokinetics have ...
Cyril Leven, Pauline Ménard, Isabelle Gouin-Thibault, Alice Ballerie, Karine Lacut, Edouard Ollier, Jérémie Théreaux   +6 more
doaj   +1 more source

Clinical pharmacology consultations and their implementation in clinical decision making

British Journal of Clinical Pharmacology, EarlyView.
Aims One of the key roles of clinical pharmacologists is to work as consultants for other medical specialties. We wanted to investigate the characteristics of clinical pharmacology consultations, compare the types of consultations from different specialties, and evaluate how well the recommendations given were followed.
Mirjam Kauppila, Janne T. Backman, Outi Lapatto‐Reiniluoto   +2 more
wiley   +1 more source